Alyeska Investment Group
FOMX

Alyeska Investment Group’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Alyeska Investment Group’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-205,870
Closed -$955K – 572
2017
Q2 		$955K Sell
205,870
-296,709
-59% -$1.32M 0.01% 416
2017
Q1 		$2.49M Sell
502,579
-151,262
-23% -$1.46M 0.02% 378
2016
Q4 		$7.26M Buy
653,841
+3,716
+0.6% +$35K 0.06% 298
2016
Q3 		$6.02M Buy
650,125
+80,722
+14% +$675K 0.06% 309
2016
Q2 		$3.62M Buy
569,403
+11,554
+2% +$76.7K 0.03% 328
2016
Q1 		$3.64M Buy
557,849
+17,247
+3% +$111K 0.03% 299
2015
Q4 		$4.38M Buy
540,602
+30,411
+6% +$227K 0.05% 266
2015
Q3 		$3.74M Buy
510,191
+39,093
+8% +$398K 0.04% 283
2015
Q2 		$4.83M Buy
471,098
+270,028
+134% +$2.98M 0.05% 275
2015
Q1 		$1.86M Buy
201,070
+14,781
+8% +$132K 0.03% 380
2014
Q4 		$1.31M Buy
186,289
+3,680
+2% +$21.1K 0.02% 375
2014
Q3 		$995K Buy
+182,609
New +$1.05M 0.02% 327

Other funds holding FOMX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Alyeska Investment Group's FOMX Position: Q3 2017 in Review

Alyeska Investment Group sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2017, closing a stake of 205,870 shares — an estimated $955K sold.

Alyeska Investment Group first reported a position in FOMX in Q3 2014 and held it in 12 quarters. The position peaked at $7.26M in Q4 2016. 45 funds tracked by Wall St. Rank hold FOMX as of Q3 2017.

  • Alyeska Investment Group reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Alyeska Investment Group sold 205,870 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2017, an estimated $955K.
  • Alyeska Investment Group first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q3 2014 and held it in 12 quarters.
  • Alyeska Investment Group's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $7.26M in Q4 2016.
  • 45 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2017.

Based on Alyeska Investment Group's 13F filing for Q3 2017, filed 14 Nov 2017.